Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024NEW YORK and ...

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

The inhibition of ERK5 is a potential complementary strategy for countering FAK inhibitor resistance in patients with lung ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug, a "protein ...

Altamira’s Senior Management will hold an investor call today, Tuesday, September 24, 2024, at 8:30 a.m. EDT its business update and first half 2024 results. Founder, Chairman, and CEO Thomas Meyer ...

To see if cryptic pockets were also present on other GTPases, Shokat and coworkers overlaid the sequence of these enzymes ...

Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and Chief Executive Officer; ...

Gig roles are emerging in India's corporate sector, with IT, pharmaceuticals, and energy firms hiring senior executives on ...